Home / Transcripts / Alamar Biosciences, Inc. (ALMR) · August 10, 2026

Alamar Biosciences, Inc. (ALMR) Earnings Call Transcript

August 10, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 46 min

Earnings Call Speaker Segments

Kari Mandeville executive
#1

Hello, everyone, and thanks for spending time with us this afternoon as we go over the financial results for Alamar Biosciences' second quarter of 2026. With me today are Yuling Luo, who serves as our Chief Executive Officer, and Justin McAnear, our Chief Financial Officer. Tod White, our President, will be available during the Q&A portion. We released a press release earlier this afternoon that lays out the details of our second quarter financial results, and an accompanying presentation has been posted in the investor section of our website. Before we get started, I want to remind everyone that what we say on this call will contain forward-looking statements as defined under applicable securities laws. Such forward-looking statements carry risks and uncertainties, and no assurance can be given by the company that they will turn out to be correct. In addition, we have no obligation to offer any further updates regarding our business trends or how we performed during the quarter. For a better understanding of the risks and uncertainties that might cause actual results to differ, please refer to the periodic reports Alamar Biosciences files with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, filed on May 8, 2026. I'll now hand the call over to Alamar CEO Yuling Luo.

Yuling Luo executive
#2

I appreciate that, Kari, and I want to thank everyone for being with us this afternoon on what marks our inaugural earnings call since becoming a public company. Before diving in, I'd like to express gratitude to our investors for the confidence and backing they showed us after our successful initial public offering; along with the whole Alamar team, we stay dedicated to generating meaningful impact as well as building long-term shareholder value. My plan is to open the call with a quick rundown of Alamar and our platform, then go through business highlights from Q2, and finish with our strategy for capturing the opportunity in front of us. After that, I'll hand things to Justin, who will walk through our financials and the revenue outlook for the rest of the year. Let's begin on slide 3. We started Alamar 8 years ago with one clear purpose: to power precision proteomics so disease can be detected as early as possible. That purpose is still our North Star. The proteomics market is a huge opportunity that remains largely untapped. Our view is that it's stayed untapped not due to insufficient demand, but due to a shortage of sensitive and sophisticated tools. That technology gap is exactly what Alamar was created to close, and I believe we're now delivering on that. Moving to slide 4. What makes Alamar distinctive is straightforward; no other platform brings together all 5 elements required for precision proteomics, ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation. Historically, existing technologies have forced a trade-off, giving up something in sensitivity, in multiplexing capability, or in workflow simplicity. Our platform was purpose-built to remove those trade-offs. Since we launched our precision proteomics platform in January 2024, adoption has been phenomenal. Let's look at our top-line results on slide 5. Q2 2026 was a strong quarter that captures the momentum in our business. Total revenue increased 82% year-over-year, powered by exceptional consumable performance. Consumable revenue made up 53% of our total revenue and rose 147% versus Q2 2025. We also reached a 60% gross margin for the first time. Now to slide 6; in the near term, we're concentrating on 3 key drivers to sustain and broaden adoption of our platform. First, expanding our instrument installed base so we reach new institutions and geographies. Second, creating novel content to extend our leadership in our beachhead neurology and inflammation research markets and move into adjacent disease areas with significant unmet need. Third, partnering with leading institutions to develop new applications, support third-party studies, and grow our publication base so awareness and adoption of our platform increase. On to slide 7. Across each of these areas, we're making meaningful progress. We keep growing our installed base, launching 3 new RUO products that broaden the reach and the utility of our platform, deepening our strategic partnership, surpassing 165 cumulative publications and preprints, and delivering our strongest scientific presence ever at Alzheimer's Association International Conference. I'll cover each of these achievements in somewhat more detail. Moving to slide 8, we'll establish a clear leadership position in neurodegenerative research. Around the middle of March, we introduced the NULISAseq Neuro 220 Panel, our new offering, and the uptake has been remarkable. Then in early July, we brought to market the first commercial multiplex blood-based immunoassay aimed at eMTBR-Tau, a marker that is increasingly recognized as among the most significant in Alzheimer's disease research. With attomolar sensitivity, our eMTBR-Tau delivers a non-invasive measurement of tau tangle burden from blood, multiplexed together with other neurodegeneration and neuroinflammation biomarkers out of one low-volume sample. Validation has been done across several cohorts, and data from numerous customer labs has already been submitted for publication. At our AAIC workshop, we presented these findings, and the response was tremendous. That laid the groundwork for our strongest AAIC showing to date. On slide 9, we left AAIC with a firm impression that this field is nearing an inflection point, and Alamar sits right at its center. Over 140 posters and presentations involving NULISA technology were counted by us — a four-fold rise compared with last year. Three takeaways from the conference strengthen our confidence about the direction the market is taking. To begin, blood-based biomarkers are becoming mainstream. Next, tau is increasingly viewed as a key drug target, with Biogen moving its tau-lowering drug into phase III and other companies doing the same. For our eMTBR-Tau launch, the timing simply could not be better. And third, appreciation keeps growing for just how complex neurodegenerative disease is. Heterogeneity and co-pathology — among them alpha-synuclein, frontotemporal dementia, and vascular disease — are drawing more and more attention from researchers, which fuels demand for the deeply multiplexed, multi-target panels that our platform alone is able to provide. On slide 10. Within large cohort studies, our leading position in neurodegenerative disease research is converting into growing use of our platform. Today, we announced an expansion of our strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, which adds profiling of another 86,000 plasma samples through our NULISAseq Neuro 220 Panel. This extends what we announced in June 2025 regarding a multicenter initiative that profiled more than 55,000 samples. Part of this expanded agreement is a national-scale initiative, co-led by researchers at three leading universities, to profile roughly 21,000 plasma samples drawn from 10,000 Alzheimer's Disease Research Center participants throughout the U.S. With completion expected in 2027, the combined dataset will cover over 140,000 samples profiled across multiple geographies and cohorts, and it will be made available to the worldwide research community via the Global Neurodegeneration Proteomics Consortium; in our view, this partnership will produce one of the most unique resources that exists today for understanding neurodegenerative disease. On slide 11. Past neurology, we are also growing content for inflammation, our other initial market. Two weeks ago, we launched the NULISAseq Immune 340 Panel, the broadest multiplex immune profiling panel we offer. It builds on the NULISAseq Inflammation Panel 250, which was our first immune panel. Chronic low-grade inflammation is the biology behind this expansion, and it is implicated across cancer, cardiovascular, metabolic disease, neurological disease, autoimmune disease, and aging. Up to this point, a great deal of that biology has remained beyond our grasp, since numerous immune mediators are present in circulation at levels that fall under what standard immunoassays can detect. Our Immune 340 Panel tackles this issue head-on, offering attomolar sensitivity while measuring roughly 340 proteins tied to immunity at once from one blood draw. It picks up the regulatory signals, feedback loops, and rare low-abundance mediators that competing platforms typically overlook. In our view, this panel unlocks a sizable market opportunity that remains under-penetrated, and in immunology we are now applying the very playbook responsible for our achievements in neurodegenerative disease. Moving to slide 12. We further broadened what our platform can do by introducing a NULISA Dried Blood Spot Extraction Kit, which allows fingerstick samples collected at home to work with our ultra-high sensitivity multiplex proteomics platform. In the past, recovering protein signals from dried blood spots of small volume without sacrificing the low-abundance biology that researchers value posed a considerable technical hurdle. With our NULISA Dried Blood Spot Extraction Kit, high target detectability is achieved across our neurology and inflammation panels through numerous micro-sampling platforms. It is our belief that gathering samples remotely at home will prove essential for enabling future population-scale screening and health monitoring tests. Moving to slide 13.

Yuling Luo executive
#3

During the second quarter, we brought in over 40 additional publications and preprints, which lifted our cumulative count to 165, covering areas like neurodegenerative disease, oncology, cardiovascular, metabolic, and autoimmune conditions. The scope and depth of this quickly expanding body of work truly underscore what our platform can do. One especially powerful illustration is from the lab of Dr. Carlos Cruchaga at Washington University, which is featured on slide 14. This study, which appeared in the Journal of the Alzheimer's Association, leveraged our platform to build an AI-based classifier that can diagnose neurodegenerative diseases and categorize co-pathology using a blood sample. What stands out most about this work is that a meticulously chosen panel of only 15 proteins achieves robust diagnostic and co-pathology classification, whereas a legacy platform needs hundreds of markers. This reinforces a core thesis behind our value proposition. If you measure the right proteins with adequate sensitivity and precision, you can beat larger, less targeted assays. A scalable, non-invasive approach to categorizing co-pathology could make clinical trials more productive and precision medicine more attainable. Now to slide 15. As I noted when the call began, the opportunity in front of us is enormous. Today we serve the research market, which is sizable by itself and projected to hit $9 billion within the next decade. However, proteomics applies broadly across disease areas, and we think our platform can extend past research into clinical diagnostics, making early detection and health monitoring possible at population scale. The genuine value comes from combining our multiplex capabilities with the sensitivity that clinical use demands; we intend to partner with companies that contribute disease domain expertise, build clinical development infrastructure, bring regulatory experience, reimbursement pathways, and commercial channels. Picture our platform as the iPhone. We supply the hardware and the operating system, and we let third parties create the applications. In our situation, those applications are differentiated diagnostic tests that our partners would develop and, where applicable, pursue regulatory marketing authorization. To capture this opportunity, we are building a clinical instrument, ARGO HT DX, and carrying out a phased diagnostic enablement strategy, which is laid out on slide 16. Step one is securing FDA marketing authorization to demonstrate that our platform clears the regulatory bar for clinical use. We think this will encourage adoption in late-phase clinical trials and create the opening for partners to develop laboratory-directed tests and IVD tests on our platform. We also think that going after FDA marketing authorization could boost usage in our space across discovery, translation, and clinical trial, since we provide something most research tools lack: an obvious route to clinical translation. After we secure FDA marketing authorization, step two involves creating high-value differentiated test offerings. With authorization secured, we intend to partner with IVD and LDT companies to help develop tests that, whether standalone or as part of multi-omic solutions, are meaningfully differentiated from what is available today. Before Justin takes over to go through the financials, I'd like to pause and recognize that we lost a member of our board, Ian Ratcliffe. The qualities that shaped Ian's whole career are the very ones he gave to Alamar: intellectual rigor, real concern for those around him, and a steadfast conviction that scientific innovation can reach patients and transform lives. His dedication to Alamar and to the wider scientific community marked his leadership, and all of us are better off because he stood with us. Proteomics is having a remarkable moment, and in my view Alamar holds a position unlike any other to guide it. What this team has achieved makes me enormously proud, and I'm excited about what comes next. So with that, I'll pass things to Justin.

Justin McAnear executive
#4

Thank you, Yuling. Since wrapping up our IPO in April, this marks the first time we've held an earnings call as a public company. Reaching this point is a significant milestone, and the team's performance across both financial and operational areas makes me proud. With that said, let me take you through the specifics of our second quarter 2026 financial results. All growth rates, unless stated otherwise, are comparisons against the same period a year ago. Our intention is to refresh the installed base and average instrument pull-through figures once a year, and we'll provide those during our year-end 2026 earnings call. Beginning on slide 17, second quarter total revenue came in at $29.4 million, which is 82% higher than the $16.2 million recorded in the second quarter of 2025. These figures demonstrate fast and wide-ranging uptake of our ARGO HT platform across the customer segments and geographies we serve. Consumables once again stood out as the strongest category, making up over 50% of total revenue for the second quarter. Consumables revenue reached $15.5 million, a 147% increase year-over-year, fueled by robust demand for our multiplex panel kits as our install base has expanded. Instrument revenue for the second quarter totaled $7.8 million, rising 35%, powered by ongoing growth in new instrument placements. We're happy with how placements are progressing, and as Yuling mentioned, the installed base is now supporting a robust and expanding recurring consumables revenue stream. Service and other revenue amounted to $6.2 million for the quarter, an increase of 49%. This category consists of our Technology Access Program, or TAP services, along with maintenance contracts. At present, TAP revenue makes up the bulk of our service revenue. Maintenance contract revenue represents a smaller share, since a substantial portion of our installed base remains under the one-year warranty. As a reminder, TAP has three main purposes: bringing in new customers, assisting with custom assay development, and beta testing new products ahead of launch. It's important to note that TAP isn't meant to be a permanent service business. Our aim is for new customers to eventually buy their own instrument or move their work to a CRO, and we deliberately run our TAP program with that transition in mind. The Q2 increase was mainly attributable to bigger custom assay development projects. As our platform keeps gaining traction and our publication base expands, we anticipate TAP services will grow more slowly than other parts of the business. Turning to the geographic split for the second quarter on slide 18, the Americas accounted for 69% of revenue, EMEA for 22%, and APAC for 9%. We're actively expanding our international footprint, and we see considerable runway in both EMEA and APAC as we strengthen distribution partnerships and direct commercial efforts in those regions. In terms of customer mix, academic and research institutions contributed 52% of second quarter revenue, biopharmaceutical companies contributed 42%, and distributors made up the remaining 6%. The ongoing momentum we're seeing in biopharma is especially encouraging, since those customers typically conduct bigger, longer-running cohort studies that generate significant consumables pull-through as time goes on. For the second quarter, gross profit came in at $17.7 million, versus $8.6 million during the same period a year ago. Our gross margin reached 60% in Q2 2026, compared with 53% in Q2 2025. That represents the highest gross margin we've ever recorded. Two main factors drove this improvement. First, we've achieved manufacturing efficiencies because consumable production has scaled up considerably, and second, there's been a favorable mix shift, with consumables accounting for a larger share of revenue, and those carry higher gross margins than instruments do. Operating expenses totaled $31.2 million in the second quarter, versus $16.5 million in the comparable prior year period. These higher costs mainly reflect intentional investments in our people, infrastructure, and R&D capabilities. R&D expenses reached $13.8 million for the quarter, a 55% jump from $8.9 million the year before. That rise stems from greater lab supply costs needed to support our growing consumable panel menu, plus higher personnel costs. SG&A expenses were $17.4 million for the quarter, climbing 129% from $7.6 million in the same period last year; the main drivers were increased personnel costs along with greater professional services fees for legal and accounting work. Our loss from operations was $13.5 million in Q2, versus $7.9 million in Q2 2025. Included in that figure is $3.3 million of stock-based compensation for Q2 2026, compared with $0.7 million for Q2 2025. Net loss came to $13.2 million for the second quarter, versus $7 million in Q2 2025. We closed out Q2 with a solid financial position. As of June 30, 2026, our cash equivalents, short-term investments, and restricted cash totaled $256.3 million. Additionally, this month we refinanced our existing debt facility with SVB First Citizens Bank, replacing it with a new revolving credit facility that's more flexible, offers better terms, and comes with more favorable pricing. At closing, $60 million is available under this facility, plus there's an extra $40 million uncommitted accordion, bringing the total to $100 million; we're glad to keep strengthening our relationship with SVB First Citizens Bank, a valuable partner that has supported our growth since long before our IPO. Our strong balance sheet is a result of our April IPO, which brought in net proceeds of $197.8 million. With this well-capitalized position, we can carry out our plan, and we plan to put this capital to work strategically to grow our organization and capabilities for future growth — expanding our commercial sales and support function, boosting manufacturing capacity, and strengthening our R&D organization to broaden product content. Now, on our outlook for the remainder of the year, we anticipate full year 2026 revenue in the range of $116 million to $120 million, which represents expected annual growth of 59% at the midpoint of that range. Looking at Q3, our top line should see a slight bump up from Q2. When it comes to costs, we plan to keep adding people in both the commercial and R&D areas, plus we'll carry the recurring expense that comes with being a publicly traded company. While we expand, our attention stays on keeping a rigorous route toward becoming profitable. And with that, I'll hand things back over to Yuling.

Yuling Luo executive
#5

Thank you, Justin. Prior to taking questions, I'd like to recognize the people at Alamar. The effort needed to get this company off the ground, finish an IPO, and turn in a quarter such as this all at once is remarkable. My gratitude goes out to each member of the team who helped make that happen. As we look toward the remainder of 2026, there are three key objectives. The first is expanding our installed base by no fewer than 100 instruments across full year 2026. That deepens the base for recurring consumable revenue. The second is keeping per instrument pull-through above $400,000, which in our view is the strongest indication that customers are operating our platform at genuine scale. The third is moving ahead into further large cohort studies, especially within translational and biopharma settings, where the need for high sensitivity multiplex protein data is greatest. As we move into 2027, the milestone becomes even more meaningful. Our plans include continuing to expand the installed base of instruments and launching a multiplex panel aimed at a new disease area, submitting the ARGO HT DX for FDA marketing authorization, and forming partnerships to advance our clinical and diagnostic enablement strategy. Our confidence in this opportunity has never been greater. We are well-capitalized, our roadmap is clear, and our team has shown it can execute; with that, we'll now take questions. Operator?

Casey Woodring analyst
#6

Thanks a lot. Appreciate you fielding my questions, and nice work on the quarter, everyone. Perhaps to kick things off, I'd like to ask about how demand looked for academic versus pharma customers during the period. Pharma, as I understand it, has been the growth engine for you folks recently. I'm just wondering whether that held true once more, and whether you could break out the growth by that type of customer. I'd also be interested to know whether you noticed any fundamental strengthening in the academic markets. Then, as a second question, regarding the instruments you placed in Q2, at a higher level, I was just wondering if you could tell us whether that growth came from additional placements with accounts you already had or from customers who are new.

Yuling Luo executive
#7

Yes. Thanks, Casey, for those questions; during Q2, we saw robust growth coming from the academic side and the biopharma side alike. Our neural offering has been adopted to an exceptional degree. I believe that's part of why we're experiencing such remarkably strong growth in the academic market. Looking ahead, we keep anticipating substantial growth in both the academic market and the research market.

Justin McAnear executive
#8

Casey, regarding the second portion of what you asked about instrument placements, you wanted to know whether we're primarily going to new customers or existing ones. Looking at this year to date, most instrument placements are going to new customers.

Yuling Luo executive
#9

And perhaps I should just mention as well that watching our current customers keep taking on another instrument is something we find pretty thrilling. For me, that serves as a solid signal that the customers we already have have discovered considerable worth and usefulness in what our platform offers, and they're eager to grow with it. A few of these expansions reach past a single site into another one, which is really great to witness.

Dan Brennan analyst
#10

Excellent, thanks, and well done on the opening quarter. Perhaps starting with that quarter, regarding the momentum in TAP, and possibly breaking down a bit of both the consumables side and the instruments side. TAP generated quite impressive expansion thanks to upside. Could you break it out for us — was there anything of a one-time character in there at all? Are you expecting TAP to keep going? Justin, I realize you mentioned modest sequential growth. I'm just curious whether that's the norm or whether that's a cautious view? Any color there would help, and then I've got one more question after that.

Yuling Luo executive
#11

Hello, Dan. We appreciate you asking those questions. We're really happy with how our consumables are being pulled through, and they grew close to 150% compared with the same period a year ago. It's also exciting to watch the TAP figure climb, and that's clearly higher than we had expected. Customer asset development is a big part of why. It's encouraging that this metric shows customers wanting to shift beyond discovery—using our platform toward translation and eventual clinical use. Our view is that, looking further out, these gains in customer revenue will lead to additional instrument or consumable purchases down the road.

Justin McAnear executive
#12

Yes, thank you. Dan, to expand on what was said regarding the TAP program, as we mentioned, there are three goals involved: bringing in new customers, helping with customer asset development, and conducting beta testing for new products before they launch. Our TAP pipeline is quite robust, and per Yuling Luo, we view it as a solid leading indicator for demand down the road. On your question about one time, I guess you could say that ideally, all of TAP would be one time, since we'd be moving on to new products. In the quarter that just passed, TAP volume came in higher than we'd anticipated. I anticipate this pattern will persist in the near term as we head into Q3, though not to the degree seen in Q2. Then there was your other question about the overall step-up from Q2 to Q3, where we describe it as a modest step-up. For me, when we say modest, that translates to low single-digit sequential growth from Q2 to Q3.

Puneet Souda analyst
#13

Yeah, hi, Yuling Luo and the team. I appreciate you taking my questions. The first one concerns pull-through. I'd like to get a better handle on that $400,000 pull-through figure you've cited and your expectation of staying above it. You went past that figure last year as well. I'm just attempting to grasp how you view that figure over a longer horizon, and its cadence. Looking at this quarter, did pull-through decline from Q1 to Q2, and is that simply because of additional installs, which in our view signals future growth in consumables; the final part of my question is, might you discuss the maximum you could achieve, considering what this platform delivers on the pull-through side? Thank you. I have one more question.

Yuling Luo executive
#14

Thank you, Puneet. Without a doubt, demand for consumables is strong. As I noted, consumables have increased nearly 150% compared with last year. In our view, it's still early. Once you bring on a new customer, that customer needs time to ramp up, and that is precisely what you described regarding pull-throughs. We stay quite confident that pull-through will remain above $400,000 during this year, which, I would remind you, leads the industry.

Justin McAnear executive
#15

One more point from me: those newly placed instruments are going to weigh on pull-through for a while, simply because of how many units we're putting in every quarter compared with how large our installed base is. So quarter-to-quarter, we'd anticipate some ups and downs in that quarterly pull-through figure — that's the reason we're giving this metric on an annual basis right now. Puneet, you also asked a second question about the ceiling for pull-through. Under an assumption of three plates within a 24-hour period, five days each week, the theoretical pull-through ceiling works out to $5 million-$6 million per instrument.

Puneet Souda analyst
#16

That's super helpful.

Yuling Luo executive
#17

I just want to-

Puneet Souda analyst
#18

Yes, go ahead, Yuling.

Yuling Luo executive
#19

Sure, I'd like to mention as well that for a lot of the pharma companies, how quickly a matter gets settled matters a great deal to them. They aren't making full use of what their instrument can handle. Instead, they'd prefer to purchase a handful of additional instruments so they can obtain results more quickly.

Puneet Souda analyst
#20

Understood.

Yuling Luo executive
#21

That's yet another factor explaining why we're able to keep the pull-through in check.

Dan Arias analyst
#22

Hey everyone, thanks for taking the questions. I'd like to ask something regarding the assay portfolio. Yuling, I'm assuming you plan to shift users of the CNS 120 panel over to the Neuro 220 Panel fairly fast. What I'm wondering is whether a validation step has to happen when that transition occurs, and whether that introduces some kind of pause or something worth considering when we think about run rates and consumable pull-through rates during that period?

Yuling Luo executive
#23

Yes. Hello, and thank you, Dan. When it comes to our product roadmap, it's quite similar to what we described during the IPO process: number one, we intend to double down on what's winning, and that means rolling out the Neuro 220 Panels, which we brought to market in March this year, and adoption has been incredible since that point; we've also doubled down on the immune panel, launching Immune 340 a couple of weeks ago. We're seeing some early signs of adoption. That has us quite excited, and as we move forward, we'll build content to cover new disease areas. Specifically, the cardiovascular and metabolic disease area, plus oncologies. So that's roughly the high-level product roadmap we're going to pursue.

Dan Arias analyst
#24

All right. Justin, I'd like to revisit the consumables pull-through rate. Looking back at the prior year, there was a substantial jump from the third quarter into the fourth. Could you address whether unusually large orders landed in last year's fourth quarter, since we're considering seasonality and attempting to rely on that period as a benchmark for the current year? I simply want to confirm we're building our models accurately during this early stage, given how little historical data we have to work with.

Justin McAnear executive
#25

Sure. Dan, I appreciate that. Regarding the fourth quarter of 2025 and the increase from Q3 to Q4, that was a fairly solid rise; we also received somewhat bigger orders tied to large cohort studies, with two specifically landing in Q4. As for how we view the Q3-to-Q4 increase in the current year, we continue to have larger cohort studies of that kind distributed across numerous quarters. If you revisit last year's Q4, those delivered disproportionate contributions simply because of their magnitude, relative to the remaining revenue base.

Dan Arias analyst
#26

All right, that's excellent. I appreciate it.

Michael Ryskin analyst
#27

Excellent. Thank you, and congratulations on the quarter. Justin, perhaps I'll keep it to the two of you regarding the P&L. Maybe first concerning the gross margin line, like you mentioned, you folks reached 60%. Strong margins across both products and services. Is there any reason that ought not to persist, since in terms of your mix it won't be all that different moving forward, it will keep skewing toward consumables, the gains in certain of your manufacturing operations as consumables increase in scale, as volume simply increases in scale, that ought to keep going. Is there any reason this ought not to be kind of the launching point moving forward for gross margins? Might you provide us the roadmap from this point regarding where that figure heads? I have a follow-up.

Justin McAnear executive
#28

Yes, I appreciate the question, Mike. When we examine our 60% gross margin for Q2, that genuinely mirrors two main drivers; namely the rising mix of consumables revenue, which carries higher margins compared to the instruments, plus the ongoing advantage of manufacturing scale and leveraging overhead. As consumables keeps growing into a bigger portion of revenue, we anticipate that driver will widen the margin in time; that additionally hinges on how rapidly our instrument installed base expands and the mix among instruments, consumables, and services. When we consider the remainder of the year, even though reaching 60% gross margin was a wonderful milestone to achieve, we do anticipate fluctuation in the near term, and I would anticipate that fluctuation to fall around the mid to high 50s, in the near term. Yet I would anticipate it to keep trending upward in time.

Michael Ryskin analyst
#29

Okay, all right. My next question concerns operating expenses — specifically R&D plus SG&A. Over the past couple of quarters, you've handled those quite effectively. The IPO has now been finished and up-sized, leaving you with a decent war chest. Throughout that process, you repeatedly mentioned how efficient your sales force is and how a very small team can generate the revenues you're bringing in. So with some of that war chest now available, has anything shifted in your thinking about the coming three, six, or 12 months regarding OpEx spending, and where do you see the opportunities — the levers you'll be adjusting? Thanks.

Justin McAnear executive
#30

Yes, I appreciate the follow-up, Mike. Regarding our capital allocation priorities, they're fairly clearly defined. These three areas would take our biggest investment: first, growing the commercial organization, aimed at driving instrument placements and increasing penetration within existing accounts. Second, building out our manufacturing capacity, which includes expanding the Fremont facility. Third, keeping up investment in R&D so we can develop new panels and new instruments — the ARGO HT DX among them — plus new applications spanning various disease areas.

Puneet Souda analyst
#31

Yeah. Hi, everyone. I just want to ask a quick follow-up. Regarding those big-scale initiatives, I was hoping you could clear something up about timing: is the 21,000 project a separate one from what you'd described before? As opposed to the Alzheimer's project, the Alzheimer's Disease Data Initiative, and the Gates Ventures project. What I'm really after is how we ought to model the samples and their timing across 2026 and 2027. Thanks.

Tod White executive
#32

Yeah. Puneet, I appreciate the follow-up. As you mentioned, there are a few of these large cohort projects, and they're going to be distributed across several quarters. Studies like these inherently involve lengthy lead times — longer than what we see with typical commercial orders. You've got to handle sample logistics, coordinate with institutions, and build out data infrastructure; all of that needs to be in place before we're able to finish the profiling at scale. My sense is that the 2026 figures are baked into our guidance, and the remainder we expect to roll out gradually during the first half of next year.

Puneet Souda analyst
#33

All right, I just wanted to get some clarity here — is that 21,000-sample effort the CLARiTI project, and is it separate from the Alzheimer's Disease Data Initiative?

Tod White executive
#34

Yes, the two are connected.

Puneet Souda analyst
#35

Got it.

Tod White executive
#36

That falls under the Gates Ventures ADDI project. One serves as a smaller component within the other.

Puneet Souda analyst
#37

Got it. Okay. All right. Thank you.

Operator operator
#38

That brings today’s conference and the Q&A session to a close. We appreciate everyone joining us, and you are now free to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alamar Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alamar Biosciences, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.